[Alpha Tau in PR Newswire] Alpha Tau announces enrollment of first patient in combination trial of Alpha DaRT™ and Pembrolizumab (Keytruda®)

Source Node: 1449913

Alpha Tau Medical Ltd. (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, announced today that it has enrolled its first patient in the combination study of Alpha DaRT and pembrolizumab (Keytruda®) at Hadassah Medical Center in Jerusalem, Israel.

Read more here.

Source: https://blog.ourcrowd.com/alpha-tau-and-healthcare-capital-corp-to-combine-and-create-a-publicly-traded-company-focused-on-transforming-the-treatment-of-solid-tumors-through-the-precision-delivery-of-alpha-radiation-2/

Time Stamp:

More from OurCrowd Blog